Inventor
BAEUERLE PATRICK
US40 patents
⚠️ This page may combine multiple inventors who share the name “BAEUERLE PATRICK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TCR2 THERAPEUTICS INC
10 patentsUS10442849B2Oct 15, 2019
Compositions and methods for TCR reprogramming using fusion proteins
TCR2 THERAPEUTICS INC21 citations93
US10208285B2Feb 19, 2019
Compositions and methods for TCR reprogramming using fusion proteins
TCR2 THERAPEUTICS INC14 citations93
US11028142B2Jun 8, 2021
Compositions and methods for TCR reprogramming using fusion proteins
TCR2 THERAPEUTICS INC6 citations83
US10358474B2Jul 23, 2019
Compositions and methods for TCR reprogramming using fusion proteins
TCR2 THERAPEUTICS INC9 citations83
US10358473B2Jul 23, 2019
Compositions and methods for TCR reprogramming using fusion proteins
TCR2 THERAPEUTICS INC4 citations83
US11242376B2Feb 8, 2022
Compositions and methods for TCR reprogramming using fusion proteins
TCR2 THERAPEUTICS INC6 citations73
US11377638B2Jul 5, 2022
Compositions and methods for TCR reprogramming using fusion proteins
TCR2 THERAPEUTICS INC1 citations72
US11085021B2Aug 10, 2021
Compositions and methods for TCR reprogramming using fusion proteins
TCR2 THERAPEUTICS INC3 citations72
US11851491B2Dec 26, 2023
Compositions and methods for TCR reprogramming using fusion proteins
TCR2 THERAPEUTICS INC1 citations62
US11965012B2Apr 23, 2024
Compositions and methods for TCR reprogramming using fusion proteins
TCR2 THERAPEUTICS INC0 citations61
WEREWOLF THERAPEUTICS INC
8 patentsUS10696723B2Jun 30, 2020
Activatable interleukin 12 polypeptides
WEREWOLF THERAPEUTICS INC15 citations93
US10696724B2Jun 30, 2020
Activatable interleukin-2 polypeptides
WEREWOLF THERAPEUTICS INC18 citations93
US11352403B2Jun 7, 2022
Activatable interleukin-2 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC6 citations84
US11981716B2May 14, 2024
Activatable interleukin-2 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC2 citations72
US11535658B2Dec 27, 2022
Activatable interleukin-2 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC2 citations72
US12534505B2Jan 27, 2026
Activatable interleukin-2 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC0 citations61
US12275769B2Apr 15, 2025
Activatable interleukin 12 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC0 citations61
US11453710B2Sep 27, 2022
Activatable interleukin 12 polypeptides and methods of use thereof
WEREWOLF THERAPEUTICS INC0 citations61
HARPOON THERAPEUTICS INC
6 patentsUS9708412B2Jul 18, 2017
Trispecific binding proteins and methods of use
HARPOON THERAPEUTICS INC66 citations97
US10954311B2Mar 23, 2021
Trispecific binding proteins and methods of use
HARPOON THERAPEUTICS INC9 citations85
US10844134B2Nov 24, 2020
PSMA targeting trispecific proteins and methods of use
HARPOON THERAPEUTICS INC12 citations85
US10849973B2Dec 1, 2020
Prostate specific membrane antigen binding protein
HARPOON THERAPEUTICS INC10 citations83
US12084518B2Sep 10, 2024
Trispecific binding proteins and methods of use
HARPOON THERAPEUTICS INC0 citations62
US11535668B2Dec 27, 2022
Inducible monovalent antigen binding protein
HARPOON THERAPEUTICS INC0 citations62
MICROMET AG
5 patentsUS7235641B2Jun 26, 2007
Bispecific antibodies
MICROMET AG167 citations98
US8007796B2Aug 30, 2011
Means and methods for the treatment of tumorous diseases
MICROMET AG69 citations96
US7919089B2Apr 5, 2011
Pharmaceutical composition comprising a bispecific antibody for EpCAM
MICROMET AG57 citations95
US7323440B2Jan 29, 2008
De-immunized MOG (poly)peptide constructs
MICROMET AG41 citations90
US7964707B2Jun 21, 2011
Anti-IL2 antibodies
MICROMET AG2 citations55